

Program Faculty	i
Sponsorship and CME Credit	ii
CME Activity Assessment and Evaluation	iv
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, and Carol S. Hart	4365s
The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors Jeffrey A. Engelman and Lewis C. Cantley	4372s
Her2-Targeted Therapies in Non–Small Cell Lung Cancer Charles Swanton, Andy Futreal, and Tim Eisen.....	4377s
Genomic Approaches to Lung Cancer Roman K. Thomas, Barbara Weir, and Matthew Meyerson.....	4384s
“Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation Sreenath V. Sharma, Michael A. Fischbach, Daniel A. Haber, and Jeffrey Settleman.....	4392s
Mouse Models of Lung Cancer Amit Dutt and Kwok-Kin Wong.....	4396s
Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Daphne W. Bell, Panos Fidias, Neal I. Lindeman, David N. Louis, Jeffrey C. Lee, Eugene J. Mark, Janina Longtine, Peter Verlander, Raju Kucherlapati, Matthew Meyerson, Daniel A. Haber, Bruce E. Johnson, and Thomas J. Lynch	4403s
Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence <i>In situ</i> Hybridization—Why, When, and How? Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, and Paul A. Bunn, Jr.	4409s
Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Pasi A. Jänne and Bruce E. Johnson	4416s
Combining Targeted Agents: Blocking the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways Alan Sandler and Roy Herbst	4421s
Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway Jim Dimitroulakos, Ian A. Lorimer, and Glenwood Goss	4426s
The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer Rogerio C. Lilenbaum	4432s
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer Bruce E. Johnson and Pasi A. Jänne.....	4436s
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer John V. Heymach, Monique Nilsson, George Blumenschein, Vassiliki Papadimitrakopoulou, and Roy Herbst.....	4441s
Novel Combinations Based on Epidermal Growth Factor Receptor Inhibition Alex A. Adjei	4446s
Targeted Therapies in Combination with Chemotherapy in Non–Small Cell Lung Cancer David H. Johnson.....	4451s

Clinical Cancer Research

12 (14)

Clin Cancer Res 2006;12:4432s-4364.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/12/14>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/12/14>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.